Search
Patexia Interest Groups

Pharma > Nova Content

In late August, we published our third annual ANDA Litigation Intelligence Report. We evaluated the stakeholders for Hatch-Waxman cases filed... Read More »
In late August, we published our third annual ANDA Litigation Intelligence Report, covering important statistics and evaluating all stakeholders in ... Read More »
Last August, we published our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape and focused on... Read More »
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the... Read More »
In late August we released our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape by providing... Read More »
Two days ago, the companies that joined forces in order to develop the first Covid vaccine that got approval for emergency use by FDA... Read More »
This morning we released our third annual ANDA Litigation Intelligence Report. The report covers high-level statistics related to Hatch-Waxman... Read More »
  The FDA evaluates the generic versions of a drug and approves them only if studies show that it is bioequivalent with the... Read More »
In early 1983, Bolar Pharmaceutical Inc. wanted to bring a generic version of the Dalmane drug, a sleeping pill, to the market. At that... Read More »
Two weeks ago, Curevac filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech over patent infringement alleging... Read More »
  Small molecule drugs have been the norm for much of medicine’s history. Only in the past decade has there been a rise ... Read More »
Last week, a bipartisan group of six U.S. senators sent a letter to USPTO asking to take measures in order to combat patent thickets... Read More »
The pandemic we just went through was one of the examples of how important is the patent system in strengthening the public health... Read More »
Global health care spending is predicted to reach $10 trillion USD during 2022 with almost 30% of it belonging to the USA. It might sound... Read More »
Earlier in August, we released our second ANDA Litigation Intelligence Report. We analyzed all parties involved in Hatch-Waxman cases and ranked the top law firms and ... Read More »
In late August, we released our second annual ANDA Litigation Intelligence Report where we evaluated all stakeholders in Hatch-Waxman cases including ANDA attorneys... Read More »
A couple of weeks ago we released our second annual ANDA Litigation Intelligence Report where we covered the rankings, statistics, and comprehensive analysis of... Read More »
Comments
vagisha singhNice points mention in this post and it was very usefull post ,thanks for post
Sep 4, 2021
vagisha singhit is nice and usefull post .thank you for post
Sep 4, 2021
Federal Circuit Summary Before Moore, Linn, and Chen.  Appeal from the United States District Court for the District of Delaware. Summary: A prior art... Read More »
Federal Circuit Summary Before Newman, Lourie, and Reyna.  Appeal from the Patent Trial and Appeal Board. Summary:  References were sufficiently... Read More »
As an introduction to this topic, please reread my post of July 5, 2017 about The Cleveland Clinic v. True Health Diagnostics, subtitled “Time to Redefine... Read More »
Menu